A Phase 1, Randomized, Double-blind, Placebo-controlled Single- and Multiple-dose Escalation Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of Oral VX-993 in Healthy Adult Subjects
Latest Information Update: 22 Jul 2024
At a glance
- Drugs VX 993 (Primary)
- Indications Pain
- Focus Adverse reactions
- Sponsors Vertex Pharmaceuticals
- 12 Jul 2024 Status changed from active, no longer recruiting to completed.
- 30 May 2024 Status changed from recruiting to active, no longer recruiting.
- 30 Jan 2024 New trial record